Empowering dialysis users and caregivers
Search for dialysis centres here
Log in to explore the world's most comprehensive database of dialysis centres for free!
Professional dialysis recruitment| Tolvaptan for polycystic kidney disease trial published in NEJM. |
 |
 |
| NEJM: Conclusions. Tolvaptan, as compared with placebo, slowed the increase in total kidney volume and the decline in kidney function over a 3-year period in patients with ADPKD but was associated with a higher discontinuation rate, owing to adverse events |
